Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation

Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Society of Nephrology 2015-05, Vol.26 (5), p.1205-1214
Main Authors: Trillini, Matias, Cortinovis, Monica, Ruggenenti, Piero, Reyes Loaeza, Jorge, Courville, Karen, Ferrer-Siles, Claudia, Prandini, Silvia, Gaspari, Flavio, Cannata, Antonio, Villa, Alessandro, Perna, Annalisa, Gotti, Eliana, Caruso, Maria Rosa, Martinetti, Davide, Remuzzi, Giuseppe, Perico, Norberto
Format: Article
Language:English
Subjects:
Adult
Bone Density - drug effects
Bone Density Conservation Agents - pharmacology
Bone Density Conservation Agents - therapeutic use
Bone Remodeling - drug effects
Calcium - blood
Clinical Research
Creatinine - blood
Cross-Over Studies
Ergocalciferols - pharmacology
Ergocalciferols - therapeutic use
Female
Humans
Hyperparathyroidism, Secondary - blood
Hyperparathyroidism, Secondary - drug therapy
Kidney Transplantation
Male
Middle Aged
Parathyroid Hormone - blood
Phosphates - blood
Postoperative Complications - blood
Postoperative Complications - drug therapy
Prospective Studies
Proteinuria - drug therapy
Vitamin D - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!